Agilent Receives FDA Approval for Expanded Use of PD-L1 IHC 22C3 pharmDx on Dako Omnis in Esophageal Squamous Cell Carcinoma, Triple-Negative Breast Cancer, Cervical Cancer, and Gastric or Gastroesoph
Go back to Agilent Receives FDA Approval for Expanded Use of PD-L1 IHC 22C3 pharmDx on Dako Omnis in Esophageal Squamous Cell Carcinoma, Triple-Negative Breast Cancer, Cervical Cancer, and Gastric or Gastroesoph| Agilent Technologies Inc (NYSE: A) | Delayed: 126.49 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $126.49 | 52 Week High | $48.63 | |||
| Open | $126.49 | 52 Week Low | $34.15 | |||
| Day High | $126.49 | P/E | 58.56 | |||
| Day Low | $126.49 | EPS | $2.16 | |||
| Volume | 580 | |||||
